Patents by Inventor David E. Kaelin

David E. Kaelin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sting agonists for treating bladder cancer and solid tumors
    Patent number: 11883420
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: January 30, 2024
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Axel Metzger, David J. Diller, David E. Kaelin
  • STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS
    Publication number: 20210290645
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Application
    Filed: June 8, 2021
    Publication date: September 23, 2021
    Applicant: Venenum Biodesign, LLC
    Inventors: Brian F. McGUINNESS, Grant GALLAGHER, Michael S. McQUENEY, Rukiye NAZAN ERASLAN, Gary SCHIEVEN, Jason TRAMA, Axel METZGER, David J. DILLER, David E. KAELIN
  • Sting agonists for treating bladder cancer and solid tumors
    Patent number: 11110106
    Abstract: Methods for treating bladder cancer and solid tumors are disclosed. The methods include administering to a patient a compound of formula 1 Pharmaceutical compositions of compound 1 are also disclosed.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: September 7, 2021
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: Brian F. McGuinness, Grant Gallagher, Michael S. McQueney, Rukiye Nazan Eraslan, Gary Schieven, Jason Trama, Venugopalareddy Bommireddy Venkata, Axel Metzger, David J. Diller, David E. Kaelin
  • Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators
    Publication number: 20100113492
    Abstract: Certain novel substituted aminopyrimidines are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.
    Type: Application
    Filed: January 22, 2008
    Publication date: May 6, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Scott Edmondson, David E. Kaelin, Randy Sweis